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 Protecting podocytes: how 
good do we need to be ? 
 Kevin V.  Lemley 1 
 Progression of many glomerular diseases has been firmly tied to a loss 
of podocytes, followed by a deterioration of glomerular architectural 
stability eventuating in segmental, and ultimately global, sclerosis. 
Recent studies have begun to clarify the nature of the autonomous 
(disease-independent) aspects of this process, as well as to explore 
mechanistically the  ‘ unreasonable effectiveness ’ of angiotensin blockade 
in slowing glomerular disease progression. Quantitative monitoring of 
podocyte loss (e.g., to assess therapy) remains a challenge. 
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 Th e fi rst indications of the importance of 
podocyte loss in the progression of kidney 
diseases came from animal models 1 and 
from cross-sectional studies of human 
disease. 2 Th e concept of podocyte  ‘ insuf-
fi ciency, ’ fi rst clearly enunciated by Rennke 
and co-workers, 1 was further developed 
by Kriz and co-workers 3,4 into the current 
canonical model for the development of 
glomerular sclerosis: a loss of podocytes 
leads to  ‘ bare areas ’ of glomerular base-
ment membrane, which in turn lead to 
formation of synechiae to Bowman ’ s cap-
sule and then to segmental and finally 
global glomerular sclerosis. 
 More recently, ingenious animal models 
have been developed in the mouse 5 and 
the rat 6 that allow a much more precise 
titration of the degree of podocyte loss than 
was possible with previous models using 
podocyte toxins such as puromycin or adri-
amycin. Th is has allowed those aspects of 
glomerular disease progression due solely 
to reduced podocyte number to be studied 
in isolation. In some sense, this represents 
the intraglomerular analog of the subtotal 
nephrectomy model  introduced decades 
ago to study the eff ects of reduced nephron 
number on renal disease progression. Also 
analogous to the subtotal nephrectomy 
model is the existence of an apparent 
threshold level of initial podocyte loss nec-
essary for the subsequent development of 
an autonomous phase of podocyte loss. 
 Fukuda and colleagues 7 (this issue) now 
present a meticulous study of the natural 
history of the autonomous progression of 
podocyte loss and consequent glomerular 
sclerosis, and their modulation through 
angiotensin blockade. Th e study is based 
largely on the authors ’ technique of tar-
geting podocytes for killing by diphtheria 
toxin (DT) in a transgenic rat model in 
which the human DT receptor (hDTR) is 
expressed under the control of the 
(human) podocin promoter. 6 Th e rodent 
analog of the hDTR does not bind DT, so 
wild-type rats are naturally resistant to its 
cytotoxic eff ects. Since, under the control 
of the podocin promoter, the hDTR is 
expressed only in podocytes of the trans-
genic rats, it is only these cells that take up 
and are killed by administered DT. Diff er-
ent levels of initial podocyte loss can be 
achieved by varying doses of DT. Other 
rat models (subtotal nephrectomy, puro-
mycin) support the generality of Fukuda 
and colleagues ’ 7 fi ndings in this model. 
 Th e authors estimate glomerular podo-
cyte number by two complementary 
methods: the thick-and-thin-section 
method to determine the number of WT-
1-positive nuclei (podocytes) per unit 
glomerular volume, and the fraction of 
glomerular tuft  staining for GLEPP1, a 
podocyte-expressed protein. In addition, 
the authors use a surrogate indicator for 
urinary podocyte loss — mRNA for the 
podocyte proteins podocin and nephrin 
in the urinary sediment. Th ese more novel 
indicators of progression are correlated 
with the incidence of glomerular sclerosis 
and quantitative proteinuria. 
 Fukuda and colleagues 7 show that a 
process of autonomous progression — based 
on ongoing podocyte loss — follows the ini-
tial loss of a threshold fraction of podocytes 
(greater than about 30 % ) induced by DT. 
Ongoing loss of podocytes  ‘ destabilizes ’ the 
glomerulus, leading to glomerular sclerosis. 
Progression can be prevented by combined 
angiotensin blockade (with enalapril and 
losartan). Interestingly, the eff ect of angi-
otensin blockade on proteinuria is quite 
rapid (presumably reflecting improved 
podocyte function), whereas beneficial 
eff ects on urinary podocyte excretion (as 
reflected in urine podocin mRNA) are 
delayed by 2 weeks. If angiotensin blockade 
is stopped, the several indices of autono-
mous progression recommence. 
 It has long been known that angiotensin 
blockade is  ‘ unreasonably eff ective ’ in pre-
venting progression of many renal diseases. 
So what does this study add to our under-
standing of how angiotensin blockade pre-
vents progression? Th e most signifi cant 
fi nding is that prevention of autonomous 
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progression seems to be closely tied to 
amelioration of ongoing, secondary podo-
cyte loss (as indicated by both urinary 
mRNA excretion and the structural indices 
of podocyte loss). Th is was the case inde-
pendent of the treatment group, suggesting 
that  ‘ off -target ’ eff ects of angiotensin block-
ade (for example, its antifi brotic eff ects) are 
of secondary importance in the broad phe-
nomenon of renal disease progression. 
 Most importantly, how does the initial 
loss of a supra-threshold number of 
podocytes lead to a secondary, ongoing 
loss of podocytes? Here, the authors pro-
vide only evidence that this secondary 
mechanism is somehow dependent on the 
actions of angiotensin II. 
 A recent refinement 8 of the murine 
model 5 based on the podocyte-specifi c 
expression of the receptor (hCD25) for 
the immunotoxin LMB2 allows a some-
what cleaner approach to exploring the 
role of podocyte – podocyte interactions in 
the phenomenon of autonomous progres-
sion. In the latter version of the model, the 
transgenic mice are chimeric for hCD25-
positive podocytes. Th us, the degree of 
podocyte killing is a function not only of 
the dose of toxin, but of the random 
expression of the hCD25 receptor in only 
some of the glomerular podocytes, poten-
tially avoiding the complication of suble-
thal injury in podocytes that were not 
initially killed by toxin exposure. Th e non-
susceptible podocytes are additionally 
labeled with a stainable marker, so they 
may be distinguished from hCD25-
expressing podocytes (or from any 
 ‘ replacement ’ podocytes that may have 
arisen from local niche populations). 
 A number of local (intraglomerular) 
mechanisms could explain the progres-
sive, autonomous loss of podocytes result-
ing from an initial supra-threshold loss. 
Some of these have been considered by 
Ichikawa and colleagues under the rubric 
of  ‘ podocyte damage damages podocytes. ’ 9 
Such mechanisms envisage a podocyte-
to-podocyte spread of injury, possibly due 
to the loss of antiapoptotic cell – cell signal-
ing between adjacent, interdigitating 
podocytes via the slit diaphragm, auto-
crine danger or death signals coming from 
injured podocytes, or deleterious eff ects 
of local protein leakage. 
 An alternative, and non-exclusive, intra-
glomerular mechanism not related to 
podocyte – podocyte interactions, however, 
may better explain the therapeutic eff ec-
tiveness of angiotensin blockade based 
on macula densa signaling and the 
tubuloglomerular feedback mechanism 
( Figure 1 ). As podocyte number decreases, 
either segmental parts of the glomerular 
tuft are lost to sclerosis, or a decreased 
number of podocytes must  ‘ stretch ’ to cover 
the fi ltration surface, leading to broadening 
of foot processes. Either factor will 
lead to a decrease in the single-nephron 
ultrafiltration coefficient, lowering the 
single-nephron glomerular fi ltration rate 
(SNGFR). An attendant decreased delivery 
of NaCl to the macula densa will lead both 
to a decrease in aff erent arteriolar resist-
ance via tubuloglomerular feedback (in 
order to increase intraglomerular capillary 
pressures and support SNGFR) and to an 
increase in local renin release from the jux-
taglomerular apparatus. Release of renin 
from the aff erent arteriole results in local 
activation of the renin – angiotensin system 
within the glomerular tuft . 10 Increases in 
angiotensin II concentration within the 
glomerulus may aff ect the podocyte actin 
cytoskeleton (perhaps via activation of 
TRPC6 channels 11 ), increasing podocyte 
stress fi bers and eff ectively counterbalanc-
ing the increased intracapillary pressures, 
thereby preserving glomerular capillary 
structure. Although transient local activa-
tion of the renin – angiotensin system in 
this way may allow adaptive alterations in 
the podocyte cytoskeleton in the face of 
short-term increases in fi ltration pressures, 
long-term local angiotensin eff ects prob-
ably contribute to an ongoing loss of podo-
cytes via a number of possible mechanisms. 
Th is may explain the 2-week lag period 
before angiotensin blockade seems to pro-
tect against podocyte loss into the urine. 
 One of the more exciting fi ndings of 
Fukuda and colleagues 7 is the possibility 
that monitoring urinary mRNA excretion 
for podocyte-associated transcripts may 
give a reliable noninvasive view of the piv-
otal intraglomerular event in progres-
sion — ongoing podocyte loss. A  ‘ liquid 
biopsy ’ has been a dream of clinical neph-
rologists for quite a while. More work is 
needed, however, before it can become a 
reality. Hara and colleagues 12 have shown 
that in addition to intact podocytes, the 
urine sediment contains fragments of api-
cal cell membranes, possibly originating 
from shedding of vesicles from podocyte 
microvilli. It is not clear whether or not 
these fragments contain mRNA from their 
podocytes of origin. So urinary mRNA 
levels may refl ect the loss of intact podo-
cytes (live and apoptotic), changes in the 
mRNA content of these intact podocytes, 
and mRNA contained in podocyte frag-
ments. Th e disparity between the urinary 
excretion patterns of nephrin and podocin 
raises the possibility that the determina-
tion of additional urinary mRNA species 
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 Figure 1  |  Mechanism for autonomous ongoing loss of podocytes once a threshold number 
are lost. Loss of podocytes and segmental sclerosis leads to decreased ultrafiltration capacity and 
single-nephron glomerular filtration rate (SNGFR). Decreased macula densa NaCl delivery triggers 
decreased afferent arteriolar resistance and increased glomerular capillary pressure (P GC ); it also 
increases release of renin from the juxtaglomerular apparatus (JGA). Local production of angiotensin 
II within the glomerulus activates podocyte stress fibers (allowing podocytes to better counter the 
increased distending pressures in the glomerular capillaries) but also may lead to additional loss of 
podocytes in the long term. Blue arrows, homeostatic pathways; red arrows, injury pathways. 
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 Atypical hemolytic uremic syndrome 
(aHUS) is the triad of microangiopathic 
hemolytic anemia, thrombocytopenia, 
and acute renal failure. Advances in the 
past 15 years have shown aHUS to be a 
disorder of the alternative pathway of 
complement. Mutations in the comple-
ment-regulatory proteins factor H ( CFH ), 
factor I ( CFI ), and membrane cofactor 
protein ( CD46 ; MCP) and complement 
components factor B ( CFB ) and  C3 all 
result in complement overactivation. 1 
 Genetic screening of people with aHUS 
is now in mainstream clinical practice 
and provides important prognostic infor-
mation that guides clinical decision 
making. With increasing genetic analysis, 
genotype – phenotype correlations have 
emerged. For instance, in patients with 
mutations in  CFH there is a very poor 
prognosis; 60 – 70 % of patients die or reach 
end-stage renal failure within a year. In 
comparison, those with  CD46  mutations 
of podocyte-expressed proteins might 
yield a richer and more informative view 
of podocyte injury and loss. 
 Th e study of Fukuda  et al. 7 also raises 
the question of whether it is possible that, 
if initial therapy in human disease can limit 
early podocyte losses to less than a certain 
threshold, 13 inexorable progression to 
renal failure may be avoided. Conversely, 
if this is not possible, will it always be the 
case that aggressive enough angiotensin 
blockade (possibly, targeted to minimize 
urinary podocyte excretion) will be suffi  -
cient to preserve glomerular architectural 
stability, protect remnant podocytes, and 
assure long-term renal survival? 
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 Interpretation of genetic 
variants of uncertain 
significance in atypical 
hemolytic uremic syndrome 
 David  Kavanagh 1 and  Holly E.  Anderson 1  
 Mutations in complement proteins predispose to atypical hemolytic 
uremic syndrome (aHUS). Mutation screening in aHUS is challenging, 
because most of the disease-associated mutations are individually rare, 
and a significant proportion of variants consist of missense mutations 
of unknown significance. The definitive interpretation of a variant of 
unknown significance (VUS) is often dependent on a reliable functional 
assay too time-consuming to be used in a diagnostic screening service. 
Allied research groups have analyzed these VUSs in aHUS. 
 Kidney International (2012)  81, 11 – 13.  doi: 10.1038/ki.2011.330 
 1 Institute of Genetic Medicine, Newcastle University , 
Newcastle upon Tyne ,  UK   
 Correspondence: David Kavanagh, Institute of 
Genetic Medicine, International Centre for Life, 
Central Parkway, Newcastle upon Tyne, NE1 3BZ, 
UK.   E-mail:  david.kavanagh@ncl.ac.uk 
have a better outcome, with about 80 % 
remaining dialysis- independent. 2 The 
genetic defect can also predict the aHUS 
recurrence rate aft er renal transplanta-
tion. 3 Th e complement-regulatory defect 
in those with mutations in the membrane-
bound  CD46 is corrected by an allograft  
bearing wild-type  CD46 . In those 
with mutations in the serum complement 
regulators  CFI and  CFH , which are pro-
duced by the liver, a renal transplant does 
not correct the defect, so the recurrence 
rate is high. Th us genetic screening deter-
mines the suitability for isolated renal 
transplantation, combined liver – kidney 
transplantation, or the prophylactic use of 
eculizumab for transplantation. 
 Mutation screening in aHUS is chal-
lenging because most of the disease-
 associated mutations are individually rare 
( Figure 1 ). In most cases, interpretation of 
the functional signifi cance of nonsense 
mutations, large gene rearrangements, and 
frameshift  mutations is clear-cut. However, 
a signifi cant proportion of variants consist 
of missense mutations or potential splice-
site changes of uncertain biologic or clini-
cal relevance. Th ese variants of unknown 
signifi cance (VUSs) pose a challenge in 
reporting the genetic results. In these 
